At Outpost, we are passionate about improving the lives of patients suffering from urologic and gastrointestinal disorders. By bringing innovative medicines to market, our goal is to truly advance patient care and quality of life. Our team of scientists and functional experts have extensive experience in drug development and commercialization, deep therapeutic expertise, and a shared commitment to scientific excellence and integrity.
The company’s lead product candidate, OP-687, is being studied for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Each of these disorders impacts more than 10% of people worldwide and current therapies do not provide adequate relief for a significant proportion of patients that suffer from them. We believe that OP-687, a new class of oral therapy, holds great potential to significantly improve the lives of patients
with OAB and IBS.
Read up on the latest pharmaceutical development news from Outpost Medicine!
- Arena’s non-core, proprietary, preclinical compound provides strategic fit with Outpost Medicine’s expertise in developing products for genitourinary disorders SAN DIEGO and INDIANAPOLIS, May 1, 2018 --Arena Pharmaceuticals, Inc.(NASDAQ: ARNA), a biopharmaceutical company focused on
INDIANAPOLIS and LONDON, Jan. 17, 2017 – Outpost Medicine, a biopharmaceutical company focused on the development of new treatments of urologic and gastrointestinal disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted
Indianapolis and London, Dec 4, 2017 – Outpost Medicine, a biopharmaceutical company focused on the development of new treatments of urologic and gastrointestinal disorders, today announced the appointment of Dr. Ian Mills as Chief Medical Officer.
New Investor Takeda Ventures Joins Syndicate; Proceeds to Fund Lead Clinical Stage Program for the Treatment of Overactive Bladder and Irritable Bowel Syndrome Indianapolis, IN and London, UK, Nov 15, 2017 –Outpost Medicine, a biopharmaceutical
LEXINGTON, Mass. and LONDON, United Kingdom, July 18, 2016 – Outpost Medicine, a biopharmaceutical company focused on the development of new treatments of urologic and gynecologic diseases and disorders, today announced additions to its senior leadership
Takeda Licenses Global Rights to Outpost for Novel Clinical Stage Compound for the Potential Treatment of Stress Urinary Incontinence Frazier Leads $41 Million Series A Financing Joined by Adams Street Partners, Novo A/S, and Vivo
